Aprea Therapeutics, Inc.

APRE

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001781983


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $15.9M
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Mar 16, 2026 237 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$0.51 2026-11-06; market equity $7.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 83.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	1.5%	(6.6%)		83.4	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 32.2						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2026-09-30						
Altman Z double-prime	not computable	(0.37)				
required facts have no common fiscal period end						
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	5.63x	2.94x		32.2	828	2025-12-31
Growth and financing, sleeve percentile 83.0						
Revenue growth, three-year compound	not computable	10.0%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 4						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(19.2%)	2.2%		83.2	696	2025-12-31
Net share issuance, one year	108.5%	2.5%		82.8	630	2026-03-16

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 108.5%
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(46.4%)	(2.1%)	18
Distance from 52-week high	(60.8%)	(30.5%)	20
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(184.8%)	(1.0%)	4
Book value to price	4.64	0.29	99
Sales to price	not computable	0.30	
Composite equity issuance, five years	259.5%	21.4%	93
Relative strength against the sector, log excess return	(0.79)	(0.19)	18

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$37.8M
Operating cash flow, four quarters	-$12.7M
Months of runway	35.7
Days since last periodic filing	4 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$84,434

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$12.6M	2025-12-31	2026-03-16	10-K	26-028068
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.9M	2025-12-31	2026-03-16	10-K	26-028068
3	assets	us-gaap:Assets	$15.9M	2025-12-31	2026-03-16	10-K	26-028068
4	assets	us-gaap:Assets	$24.0M	2024-12-31	2026-03-16	10-K	26-028068
5	current assets	us-gaap:AssetsCurrent	$15.6M	2025-12-31	2026-03-16	10-K	26-028068
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.8M	2025-12-31	2026-03-16	10-K	26-028068
7	assets	us-gaap:Assets	$22.7M	2023-12-31	2025-03-25	10-K	25-003588
8	assets	us-gaap:Assets	$30.2M	2022-12-31	2024-03-26	10-K	24-003886
9	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,452,452	2026-03-16	2026-03-16	10-K	26-028068
10	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,491,953	2025-03-25	2025-03-25	10-K	25-003588

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.